Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

1352 - Response evaluation of cancer therapeutics in metastatic breast cancer to the bone: a single arm phase 2 study of whole-body magnetic resonance imaging

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Staging and Imaging

Tumour Site

Breast Cancer

Presenters

Michael Kosmin

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

M. Kosmin1, A.R. Padhani2, A. Gogbashian2, D. Woolf3, M. Ah-See1, P. Ostler4, S. Sutherland1, D. Miles1, J. Noble5, A. Marshall6, J. Dunn6, A. Makris1

Author affiliations

  • 1 Breast Cancer Research Unit, Mount Vernon Cancer Centre, HA6 2RN - Northwood/GB
  • 2 Radiology, Paul Strickland Scanner Centre, HA6 2RN - Northwood/GB
  • 3 Clinical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 4 Clinical Oncology, Mount Vernon Cancer Centre, HA6 2RN - Northwood/GB
  • 5 Medical Oncology, The Royal Marsden Hospital, SM2 5PT - Sutton/GB
  • 6 Warwick Clinical Trials Unit, University of Warwick, CV4 7AL - Coventry/GB
More

Resources

Abstract 1352

Background

Accurate and reliable evaluation of response to systemic anti-cancer therapy (SACT) is fundamental in the management of metastatic breast cancer (MBC). CT and bone scans (BS) have significant limitations in assessing SACT response in bone disease in MBC, whereas whole-body magnetic resonance imaging (WB-MRI) shows significant promise. Published retrospective data show that the addition of WB-MRI to body CT alters treatment decisions in MBC. The primary objective of this study was to evaluate whether WB-MRI identifies progressive disease (PD) earlier than CT scans in patients with bone-only MBC.

Methods

Participants were enrolled when starting first or subsequent SACT for bone-only MBC, as established initially by BS and CT thorax, abdomen and pelvis. Baseline WB-MRI was performed within 2 weeks of trial entry. CT and WB-MRI were performed every 12 weeks until definitive PD was evident in one or both modalities. At PD, BS was assessed for bone disease progression. Radiologists independently reported CT, WB-MRI or BS and were blinded to the other modalities. Participant questionnaires were undertaken at weeks 12 and 36 to evaluate tolerability and satisfaction with WB-MRI and CT.

Results

Forty-five participants were enrolled, with a median time on-study of 24 weeks (range 1-84 weeks). Two patients were excluded due to unequivocal liver metastases on baseline WB-MRI; two had clinical progression before imaging PD; one was lost to follow up. Twenty-nine have had PD on imaging; eleven continue on-study. In 65.5%, PD was evident on WB-MRI only; 34.5% had PD on CT and WB-MRI concurrently; none had PD on CT only (McNemar’s test p < 0.0001). PD on BS was reported in 55.6% of cases of bone CT/MRI progression. Overall questionnaire response rate was 63.8%. No differences were found between CT and WB-MRI in levels of concern, comfort or pain at week 12 or 36. All participants reported satisfaction levels as ‘good’ or ‘very good’ for both modalities.

Conclusions

WB-MRI identifies PD before CT in most patients with bone-only MBC. Further studies will evaluate whether earlier identification of PD with WB-MRI and earlier SACT changes can lead to improved patient outcomes.

Clinical trial identification

NCT03266744.

Legal entity responsible for the study

East and North Hertfordshire NHS Trust.

Funding

Paul Strickland Scanner Centre.

Editorial Acknowledgement

Disclosure

M.-L. Ah-See: Consulting or advisory role: AstraZeneca, Novartis, Pierre Fabre, Merck Sharp and Domme; Honoraria: Roche. A. Marshall: Educational research grant: Bayer AG outside of this submitted work that was used in part to pay for salary for research undertaken. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.